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Abstract 
Both neurotrophin-based therapy and neural stem cell (NSC)-based strategies have 
progressed to clinical trials for treatment of neurological diseases and injuries. Brain-derived 
neurotrophic factor (BDNF) in particular can confer neuroprotective and neuro-regenerative 
effects in preclinical studies, complementing the cell replacement benefits of NSCs. 
Therefore, combining both approaches by genetically-engineering NSCs to express BDNF is 
an attractive approach to achieve combinatorial therapy for complex neural injuries. Current 
genetic engineering approaches almost exclusively employ viral vectors for gene delivery to 
NSCs though safety and scalability pose major concerns for clinical translation and 
applicability. Magnetofection, a non-viral gene transfer approach deploying magnetic 
nanoparticles and DNA with magnetic fields offers a safe alternative but significant 
improvements are required to enhance its clinical application for delivery of large sized 
therapeutic plasmids. Here, we demonstrate for the first time the feasibility of using 
minicircles with magnetofection technology to safely engineer NSCs to overexpress BDNF. 
Primary mouse NSCs overexpressing BDNF generated increased daughter neuronal cell 
numbers post-differentiation, with accelerated maturation over a four-week period. Based on 
our findings we highlight the clinical potential of minicircle/magnetofection technology for 
therapeutic delivery of key neurotrophic agents. 
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1. Introduction 
 
Following brain/spinal cord injury, the pathological microenvironment differs substantially 
from that of the normal endogenous tissue, with detrimental effects at the local tissue level, 
resulting in little or no tissue regeneration. Therefore, in order to stimulate neural repair, the 
injury microenvironment critically requires manipulation towards a pro-regenerative profile, 
through strategies such as induced expression of neurotrophins e.g. brain-derived 
neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and nerve growth 
factor (NGF) [1–4]. In this context, genetically engineered stem cell-based strategies offer 
both direct (donor cells for repopulation of lost cells) and indirect (support via secretion of 
neurotrophic factors) advantages to facilitate and accelerate cell repair and regeneration. This 
combinatorial approach (i.e. fusion of gene therapy and cell-based therapeutics) is considered 
to be an attractive and clinically relevant approach for repair of complex pathologies such as 
injuries of the brain and spinal cord [5].  
 
Of the heterogenous population of cells present in the central nervous system (CNS), neurons 
are particularly challenging to replace and repair following injury. BDNF has been widely 
validated as a therapeutic target given its beneficial effects in several neurological conditions 
such as Alzheimer’s Disease, Parkinson’s Disease, epilepsy and brain/spinal cord injuries 
[6,7]. For example, intravenous BDNF administration has been shown to reduce infarct size 
of cerebral ischemia in a rat stroke model [8]. Intrathecal delivery of recombinant methionyl 
human BDNF for treatment of Amyotrophic Lateral Sclerosis has progressed to clinical trials, 
and appears to be well-tolerated and feasible. However, investigations of a sufficient number 
of cases is required before conclusions can be drawn regarding the clinical efficacy of this 
therapy [9]. These studies highlight the benefits of a combinatorial approach for neurological 
repair and neurorestoration; transplantation of genetically engineered NSCs can facilitate 
such an approach. Indeed, promising results were observed using cell-based therapies, for 
example, grafted BDNF-expressing NSCs in a murine model of stroke enhanced 
neurogenesis, showed neuroprotective properties (reduced apoptosis) and induced 
angiogenesis with functional recovery demonstrated by improved locomotor function [10].  
 
These BDNF delivery studies almost exclusively employ virus mediated gene delivery but 
safety and scale-up issues pose major barriers to the clinical translation of this approach [11–
14]. Non-viral magnetofection methods, using magnetic nanoparticles (MNPs) in conjunction 
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with oscillating magnetic fields can offer a safe solution for gene delivery in neural cells [15-
23] but a major challenge encountered has been reduced transfection associated with 
increased size of therapeutic plasmids [23-27] (discussed in detail in Part I). 
 
In this context, we have proved (using reporter gene sequences) that minicircles (mCs) are 
ideal DNA constructs for neural gene delivery in combination with magnetofection (see part I 
of manuscript). These mini-DNA vectors are devoid of the bacterial backbone structure 
typically present in all plasmid vectors (making them safer), but also increasing gene transfer 
efficacy (up to ca. 54%) due to their small size, both of critical importance for clinical 
translation. [28] We and others have reasoned that the superior transfection efficiency is 
likely due to mC engineered cells containing higher transgene copies per cell versus 
conventional plasmids. The mC vectors are also compliant with regulations on the use of 
medicinal products for gene transfer which restrict the use of selection markers due to their 
substantial potential to impact therapeutic outcomes [29–33]. Despite the obvious clinical 
translational benefits offered by this genetic modification methodology for regenerative 
neurology, the feasibility of mC based delivery of therapeutic genes to neural transplant 
populations has never been evaluated. Accordingly, the objectives of this study are to: (i) 
demonstrate the feasibility of using mC-functionalized MNPs for BDNF gene delivery into 
primary NSCs (ii) assess the safety profile of this approach, (iii) validate the short-term and 
long term functional effects of BDNF using an in vitro neuronal cell-based assay. 
 
2. Methods 
 
2.1. Materials 
Cell culture reagents were obtained from Invitrogen and Sigma. Cell culture grade plastics 
were from Fisher Scientific. Human recombinant epidermal growth factor (EGF) and human 
BDNF Quantikine ELISA kit were from R&D Systems Europe Ltd. (Abingdon, UK). 
Transfection-grade magnetic particles, NeuroMag were from OZ Biosciences, Marseille, 
France. The magnefect-nano 24-magnet array system was purchased from nanoTherics Ltd. 
(Stoke-on-Trent, UK). Reagents used for the mC DNA production were obtained from 
System Biosciences (SBI; Mountain View, CA, USA). Kits for plasmid and mC DNA vector 
purification (both minipreps and maxipreps were from Qiagen, UK. All restriction/cloning 
enzymes were purchased from Promega, UK. Primary antibodies were: NSC markers, nestin 
(clone 25, BD Biosciences, Oxford, UK) and SOX2 (Millipore, UK); neuronal marker, class 
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III β-tubulin (clone TUJ1, Covance, Princeton, NJ, USA); the oligodendrocyte marker, 
myelin basic protein (MBP; clone 12, AbD Serotec, Kidlington, UK); the astrocytic marker 
glial fibrillary acidic protein (GFAP; DakoCytomation, Ely, UK), GFP (ThermoFisher 
Scientific, Rockford, IL,USA), Ki-67 (Abcam, UK) and BDNF (Promega, UK). Secondary 
antibodies (either Cy-3 and FITC-conjugated) were from Jackson Immunoresearch 
Laboratories Ltd (Westgrove, PA, USA). Vectashield mounting medium with the nuclear 
stain 4’,6-diamidino-2-phenylindole (DAPI) was from Vector Laboratories (Peterborough, 
UK).  
 
2.2. NSC culture 
The care and use of all animals used in the production of cell cultures were in accordance 
with the Animals Scientific Procedures Act of 1986 (UK).   
 
NSCs were generated from CD1 mice (postnatal days 1-3). Briefly, whole brains were 
harvested and the subventricular zone was microdissected, dissociated into a single-cell 
suspensions. NSCs were cultured as neurospheres (free floating cell clusters) in neurosphere 
medium (NS-M) comprising a DMEM:F12 (3:1 mix) containing B-27 supplement (2%), 
penicillin (50 U/ml), streptomycin (50 μg/ml), heparin (4 ng/ml), bFGF and EGF (20 ng/ml 
each). Neurospheres were fed every 2-3 days and passaged every 6 days using an Accutase-
DNaseI mix.  
 
2.3. Monolayer cultures  
To prepare two-dimensional adherent NSC monolayers, neurospheres (passages 0 – 2) were 
dissociated with accutase-DNase I, cells resuspended at 1.5 x 10
5
 cells/ml monolayer culture 
medium (ML-M; comprising of a DMEM:F12 (1:1 mix) with N2 supplement (1%), penicillin 
(50 U/ml), streptomycin (50 μg/ml), heparin (4 ng/ml), FGF2 and EGF (20 ng/ml each). 
NSCs were plated on polyornithine/laminin-coated coverslips in 24-well plates (0.6 ml 
suspension/well) and cultured at 37 ºC in 95% air:5% CO2.   
 
 
2.4. NSC differentiation 
NSCs were differentiated to the three major daughter cell types (neurons, astrocytes, 
oligodendrocytes) by replacing ML-M with differentiation medium (DF-M) consisting of NS-
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M (without growth factors) and supplemented with fetal bovine serum (0.5%). Medium was 
changed every 2-3 days. Cells were maintained in the differentiated state for up to 4 weeks. 
 
2.5. Construction of BDNF overexpression parental and mC DNA 
A mC system was employed to address the influence of plasmid size and copy number on the 
efficacy of MNP-mediated gene transfection. This system comprises of a parental plasmid 
pMC.EF1α-MCS-IRES-GFP-SV40PolyA (herein termed pp-BDNF-GFP; size: 8084 bp) 
from which the mC DNA vector is derived through the mC induction protocol described 
below. Such IRES vectors allow for the expression of the gene of interest and reporter gene 
separately but simultaneously facilitating the detection of the expression of the insert.  
 
BDNF coding sequence was amplified by PCR from a plasmid containing human BDNF 
coding sequence (Dharmacon Research Inc, GE Healthcare Life Sciences, UK) using the 
following primers: 
Forward: 5’ GCGAATTCATGACCATCCTTTTCCTTACTATGG and  
Reverse: 5’ GGGATCCTATCTTCCCCTTTTAATGGTCAATGTACAT.   
The EcoRI and BamHI restriction sites are underlined respectively. The PCR products were 
cloned into the EcoRI and BamHI sites of pp-BDNF-GFP. Recombinant mCs (mC-BDNF-
GFP; size 4075 bp) lacking extraneous bacterial backbone sequences were prepared from pp-
BDNF-GFP, which were transformed into specifically engineered E. coli strain which was 
induced to express ϕC31 integrase and SceI endonuclease upon addition of arabinose (0.01% 
final concentration), as per the manufacturer’s instructions. The integrase splits the full size 
pp-BDNF-GFP construct to (i) the backbone sequence containing SceI sites for targeted 
endonuclease degradation and (ii) mC DNA containing only the expression cassette which 
was purified. Thus it is possible to obtain DNA vectors that are markedly reduced in size 
whilst retaining the expression cassette containing both the therapeutic gene and the reporter 
gene. Endotoxin-free plasmids were purified according to the manufacturer’s instructions 
(Qiagen, UK). Following mC purification, restriction enzyme digests of both pp-BDNF-GFP 
and mC-BDNF-GFP were run on a 1% agarose gel in order to demonstrate (i) the presence of 
the BDNF insert in both vectors and (ii) the absence of pp-BDNF-GFP contamination in mC-
BDNF-GFP stocks. In the presence of contamination, mC-BDNF-GFP was digested with 
mC-safe DNase according to the manufacturer’s instructions. Cloned inserts were sequenced 
(outsourced to Source Bioscience, UK) to verify the integrity of BDNF within the construct. 
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2.6. Magnetofection of NSC cultures 
For magnetofection experiments of NSC monolayers, medium was replaced with fresh ML-
M (0.225 ml) before addition of transfection complexes. The particle-DNA complexes were 
prepared by mixing 170 ng of mC-BDNF-GFP and 0.62 µl Neuromag in 75 µl DMEM:F12 
(1:1) base medium for each well. Following incubation for 20 min at room temperature (RT), 
the entire mixture was added to the cells. Plates were returned to the incubator, and exposed 
to a magnetic field using the magnefect-nano oscillating magnetic array system, with a 24-
magnet array (NdFeB, grade N42; field strength of 421 ± 20 mT) with an oscillating 
frequency of 4Hz (amplitude = 0.2 mm). The array moves laterally with oscillation frequency 
and amplitude controlled via a computerised motor. For single transfection, complexes were 
left for 48 h until fixation. For double transfection, the same protocol as above was followed, 
with a 24 h time window between the first and second transfection. Cells were either fixed (to 
assess transfection efficacy, ‘stemness’ and viability), or differentiated (to assess NSC 
differentiation potential) 48 h after the first transfection. 
 
2.7. Immunocytochemistry 
Paraformaldehyde-fixed cells were blocked (5% normal donkey serum in PBS-0.3% Triton-
X-100) for 30 min at RT, followed by primary antibody incubation overnight at 4°C. The 
following antibodies (diluted in blocking solution) were added: Glial fibrillary protein (GFAP 
for astrocytes), 1:500, beta-Tubulin (Tuj1 for neurons), 1:1000, myelin basic protein (MBP 
for oligodendrocytes), 1:200 and GFP 1:1000. GFP immunostaining enhanced GFP detection 
in all cell types as previously reported (see manuscript part I). Secondary antibodies (either 
Cy3- or FITC-labelled) were diluted in blocking solution at 1:200 and were added to cells 
and incubated for 2h at RT. Following PBS washes, coverslips were mounted with 
Vectashield mounting medium containing DAPI. 
 
2.8. Enzyme linked immunosorbent assay (ELISA) 
At specific time points (48h, 5 days, 2 weeks and 4 weeks post transfection), the supernatant 
was collected, centrifuged (to remove cells and cell debris) and processed for ELISA. BDNF 
protein concentration in cell supernatants was determined using an ELISA kit specific for 
human BDNF (Quantikine® ELISA, R&D Systems) according to the manufacturer’s 
instructions.  
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2.9. Microscopic analysis 
For fluorescence imaging, an AxioScope A1 microscope equipped with an Axio Cam ICc1 
digital camera and AxioVision software (version 4.7.1, Carl Ziess MicroImaging GmbH, 
Goettingen, Germany) was used. For quantitative analyses, a minimum of 200 cells were 
counted across random fields using Image J software. For assessing neurite outgrowth, 
NeuronJ was used. Cells were identified by fluorescence microscopy using cell-specific 
immunological markers co-localised with their nuclei using DAPI. Percentage transfection 
efficiency was determined by counting the number of cells co-expressing GFP and cell-
specific markers. NSC proliferation was assessed by counting cells positive for Ki-67 (a 
proliferation-specific marker), as well as, by quantifying their absolute numbers per field.    
Neuronal morphometric quantification and analysis was carried out using NeuronJ. Neurite 
length was measured at the 2 week post-transfection time point, i.e.  the condition at which 
neurites can be measured without interference from overlapping neurites.  
 
2.10. Statistical analyses 
Treatment groups were analysed by either independent sample t-tests or one-way analysis of 
variance and Bonferroni’s multiple comparison test using Prism software (version 4.03; 
Graphpad, USA). Each error bar represents the standard deviation of a minimum of three 
separate experiments. The number of experiments denoted (n) refers to the number of NSC 
cultures, each generated from a different CD1 mouse litter. 
 
3. Results and Discussion 
 
3.1. High purity of NSC primary cultures and DNA constructs encoding BDNF 
Nestin- and Sox2-specific immunostaining of NSCs demonstrated high culture purity (95.2 ± 
1.1% and 97.9 ± 0.5% respectively, n=3 cultures). The two DNA constructs employed in this 
study were of high purity and encoded the full length human BDNF protein. The IRES- 
containing bicistronic parental plasmid (pp-BDNF-GFP, Fig. 1A) was engineered to 
incorporate the BDNF insert resulting in co-expression of BDNF and GFP, driven by the 
Elongation Factor 1α (EF1a) promoter. Systematic studies investigating the quantitative 
comparison of constuitive promoters using lentiviral vectors in various cell types (including 
mesenchymal stem cells and embryonic stem cells) report that the EF1a promoter is a strong 
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promoter in cell lines derived from rodents, humans and macaques [34–36]. pp-BDNF-GFP 
was used to generate two circular DNA entities (i) mC DNA (mC-BDNF-GFP, Fig. 1A) 
which was purified for use in the study and (ii) the bacterial backbone which is excised and 
degraded during the process of mC induction. EcoRI and BamHI restriction digests of both 
constructs (Fig.1B) revealed the expected fragment sizes (the high molecular weight fragment 
corresponds to the vector and low molecular weight fragment corresponds to the BDNF 
insert) and also demonstrated the absence of parental plasmid contamination in the mC 
preparation. Comparable results were obtained from two separate preparations of mC-BDNF-
GFP demonstrating the high reproducibility of the mC induction protocol employed in the 
study (Fig. 1B). 
 
 
 
Fig. 1. Minicircle derivation, DNA vector maps and purity of vector preparations. (A) 
Schematic showing the generation of mC-BDNF-GFP from pp-BDNF-GFP following L-
arabinose induced (i) recombination between attB and attP sites (present in pp-BDNF-GFP) 
and (ii) SceI endonuclease initiated degradation of the bacterial backbone.(B) Agarose gel 
electrophoresis micrograph of EcoRI and restriction BamHI digests of pp-BDNF-GFP (Lane 
1) and two independent preparations of mC-BDNF-GFP (Lane 2 and 3) run alongside a 10 
kB DNA marker (Lane 4). The DNA fragment corresponding to the DNA vector (i.e. parental 
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plasmid or minicircle) is denoted by arrows, arrowheads denote the BDNF insert. (bp = base 
pairs; kB = kilobases). 
 
3.2. Minicircle DNA exhibits dramatically superior NSC transfection efficiencies 
compared to its corresponding parental plasmid  
Immunostaining for GFP significantly enhanced protein detection as depicted in Fig. 2A; 
native GFP expression is shown in the inset. Therefore all samples were processed for GFP 
immunostaining prior to analysis for transfection efficiency. Transfection with both 
constructs, pp-BDNF-GFP and mC-BDNF-GFP, resulted in GFP expression throughout the 
cell body including cell processes. GFP
+
 cells appeared to express elevated levels of BDNF 
expression (Fig. 2B) compared to untransfected cells. Microscopic observation at high 
magnification revealed a punctate staining profile of BDNF throughout the cell body, 
indicative of BDNF packaged within vesicles. Dense perinuclear localization of BDNF was 
observed in most cells representing the highly active endoplasmic reticulum/Golgi apparatus, 
for protein synthesis and packaging (Fig. 2C) [37].  Double transfection (multifection) was 
carried out in all experiments as it results in higher transfection efficiencies than single 
transfection in experiments using reporter plasmids [38]. NSCs multifected with mC-BDNF-
GFP reported higher transfection efficiencies compared to pp-BDNF-GFP (transfection 
efficiency range 28.9 – 21.8% vs 4.4 - 3.9% respectively) (Fig.2 D -F). Having determined 
that BDNF is expressed within cells, BDNF secretion was verified at 24 hours following the 
second transfection.  mC-BDNF-GFP engineered cells showed approximately a 20-fold 
increase in secretion levels compared to untransfected NSCs (Fig. 2G). In comparison, pp-
BDNF-GFP transfection resulted in a two-fold increase in BDNF secretion.  
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Fig. 2. Enhanced therapeutic gene transfer in NSC monolayers using minicircles versus 
parental plasmid. (A) Representative image of GFP immunostained NSC monolayers 
transfected with mC-BDNF-GFP demonstrating enhanced GFP detection (equivalent 
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unstained image is shown in inset with corresponding cells shown by arrows/arrowheads). 
(B) Representative double-merged image of GFP-immunostained mC-BDNF-GFP 
engineered NSC monolayers (equivalent BDNF expression is shown in inset, arrow points to 
same cell in both images). (C) High magnification micrograph displaying BDNF
+
 dense 
punctate staining within the cell cytoplasm (corresponding GFP staining shown in inset). 
Representative image of GFP immunostained NSC cultures multifected with (D) pp-BDNF-
GFP and (E) mC-BDNF-GFP; insets show corresponding DAPI labelled cells, indicating 
similar cell densities across conditions (F) Bar graph showing comparative transfection 
efficiencies between pp-BDNF-GFP and mC-BDNF-GFP following double transfection in 
NSCs. (G) BDNF secretion levels in media (measured by ELISA) following double 
transfection of NSCs with pp-BDNF-GFP and mC-BDNF-GFP in comparison to 
untransfected controls. Error bars represent standard error of the mean; ***p < 0.001, 
versus pp-BDNF-GFP (student’s t-test), n=3 cultures for both graphs. 
 
3.3. BDNF overexpression promotes NSC proliferation  
 
BDNF overexpression resulted in a significant increase in NSC number compared to non-
transfected cells as judged by DAPI staining (average cell number per field: 224 ± 14 for 
untransfected vs 288 ± 12 for mC-BDNF-GFP) (Fig. 3A, B and G). An increased number of 
Ki-67
+
 NSCs was observed in parallel in the mC-BDNF-GFP condition compared to 
untransfected counterparts (Fig. C-F and H). It is important to note that the NSC monolayer 
media contains both EGF and bFGF implying that in combination with these mitogenic 
factors, BDNF may have a synergistic effect on NSC proliferation [39]. Due to this overall 
proliferative effect of BDNF on NSCs, the actual transfection efficiency reported here is 
therefore likely to be an underestimate of the initial transfection levels. The result here 
demonstrates the functional effects of the encoded BDNF as it is known to be involved in 
NSC proliferation, among many other cellular processes such as neural differentiation and 
maturation [40]. Our study shows that the BDNF levels induced are sufficient to have a 
functional biological effect on NSCs. As an example, transplantation of a mixed population 
of VEGF-engineered NSCs (transduction efficiency of ca 20-30% obtained in this study) 
demonstrated neuroprotective effects and increased angiogenesis in intact non-disease brains 
[41].  The proliferative effects of BDNF on NSCs can be predicted to be advantageous for ex 
vivo gene therapy, resulting in genesis of increased numbers of progenitor populations that 
can in turn result in enhanced production of neurons [40]. While such enhanced division does 
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raise issues related to safety of the procedures, we consider that the observed enhancement of 
proliferation is unlikely to be an issue of major clinical concern given that the default fate of 
NSCs has repeatedly been shown to be differentiation towards the neuronal and glial 
phenotypes, along with a loss of proliferative capacity [42]. However, this will need to be 
robustly tested using transplantation of mC engineered neural transplant cells delivered to in 
vivo models of neurological injury.  
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Fig. 3. BDNF overexpression results in increased NSC proliferation. Representative 
micrographs of untransfected and mC-BDNF-GFP engineered NSCs respectively showing 
(A, B) DAPI
+
 staining, (C, D) corresponding immunostaining for proliferation marker Ki-67 
and (E, F) DAPI
+
/ Ki-67
+
 double merged images. Bar graphs showing quantification of (G) 
average cell number per field and (H) proportion of Ki-67
+
 cells for both groups. Error bars 
represent standard error of the mean; *p < 0.05, **p < 0.01 versus untransfected NSCs 
(student’s t-test), n=3 cultures for both graphs. 
 
3.4. mC-BDNF-GFP engineered NSCs exhibit normal cell stemness and viability 
No observable differences in cell morphology and adherence were identified between the 
untransfected and mC-BDNF-GFP transfected conditions. Normal bipolar cell morphologies 
with round nuclei were observed indicating healthy cells (Fig. 4A) under both conditions. 
Quantification of propidium iodide (a fluorescent marker for cell death) stained nuclei 
(indicated by arrows in Fig. 4A) demonstrated no differences in cell viability between the two 
conditions (Fig. 4B). Transfected NSCs also retained their stem cell specific marker 
expression profile for Nestin, a cytoskeletal protein (Fig. 4C) similar to untransfected cells 
(Fig. 4D). Similarly assessment of another marker for undifferentiated stem cells, Sox2 
transcription factor (Fig.4E) showed no differences in the proportions of Sox2
+
 cells between 
the two groups (Fig. 4F). These results demonstrate that NSC multifection with mC-BDNF-
GFP does not affect NSC cellular health and physiology. We consider that this high safety 
profile is of critical importance, as evidenced here and in our previous study (see manuscript 
part I), emphasizing the translational potential of mC mediated engineering for cell-based 
therapies. Although BDNF is known to drive differentiation towards neuronal phenotypes, 
our data suggests that BDNF in the presence of mitogenic factors which maintain 
pluripotency such as EGF and bFGF (present at high concentration in the media) does not 
induce differentiation [43]. 
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Fig.4. Safety assessments of mC-engineered NSCs expressing BDNF. (A) Representative 
triple merged image of mC-BDNF-GFP multifected NSCs showing propidium iodide (PI) 
staining, a nuclear marker for cell death. (B) Bar graph quantifying the proportion of PI
+ 
nuclei in untransfected and mC-BDNF-GFP multifected groups. (C) Representative triple 
merged image of mC-BDNF-GFP multifected NSCs showing immunostaining for Nestin- a 
cytoskeletal NSC marker. (D) Bar graph quantifying proportion of Nestin
+ 
cells in 
untransfected and mC-BDNF-GFP transfected groups. (E) Representative triple merged 
image of mC-BDNF-GFP engineered NSCs showing immunostaining for Sox2- an NSC 
specific transcription factor. (F) Bar graph quantifying proportion of Sox2
+ 
nuclei between 
untransfected and mC-BDNF-GFP transfected groups. Error bars represent standard error 
of the mean. 
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3.5. The differentiation potential of BDNF transfected NSCs is skewed towards 
increased neurogenesis  
 
Following transplantation in vivo, it is well established that NSCs spontaneously differentiate 
into neuronal and glial lineages [38]. Following multifection, NSCs were induced to 
differentiate (by removal of growth factors from the medium) in order to examine the 
potential of NSCs to give rise to the three main daughter cell types (neurons, astrocytes and 
oligodendrocytes; the relative cell proportions usually generated are ca. 20%, 75% and 5% 
respectively). Microscopic assessment of the daughter cells showed normal morphologies, 
adherence and staining profiles. Untransfected NSCs generated ca. 18% neurons while 
BDNF engineered NSCs showed approximately two-fold increase in neurons generated (up 
to ca. 38%) (Fig. 5A-C). A previous study using SVZ-derived NSCs from rats reported that 
addition of  BDNF in the media generated a marked increase (approximately 14-fold) in the 
number of neurons (2.6% vs 35.3%, control vs BDNF-containing differentiation media) [44]. 
It is important to note that the amount of BDNF administered in the previous study was 
10ng/ml, ~10x higher than the concentration measured from the media supernatants in our 
study (ca.1ng/ml). Our data is in line with previous studies where BDNF induction led to a 
two-fold increase in neuronal numbers [45]. A possible explanation for this phenomenon is 
that the presence of BDNF influences the fate of these uncommitted progenitor cells, 
therefore favouring differentiation towards neurons [45]. Moreover, several studies have also 
reported that BDNF promotes the survival of neurons, which could account for the significant 
increase in neuronal numbers in the mC-BDNF-GFP condition [46–48]. 
 
In parallel with increased genesis of neurons, the number of astrocytes generated was reduced 
significantly while oligodendrocyte numbers were similar between the two groups in our 
study (Fig. 5C). Of the differentiated progeny, astrocytes were the predominant GFP
+ 
cell 
types (Fig.5D) as reported earlier  (see manuscript part I) [49–51]. GFP expression was co-
localised with extensive BDNF expression within cells (Fig. 5E). Neurons (Fig. 5F) and 
oligodendrocytes (Fig.5G) were rarely observed to be GFP
+
. This finding is in contrast to our 
previous report using magnetofection/mC mediated reporter gene delivery using mC-GFP 
which resulted in relatively higher numbers of GFP
+ 
neurons and oligodendrocytes. This 
highlights the potential significance of using smaller size DNA vectors for cell specific 
transfection since mC-GFP (1.5kb in size) is approximately 2.6 smaller than mC-BDNF-GFP 
(4kb) used in this study. These findings also highlight the importance of using separate mC 
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constructs for delivery of multiple therapeutic genes instead of multicistronic constructs 
(multi-gene co-expression vectors resulting in increased construct size) for cell specific 
engineering applications.  
 
Fig. 5. BDNF overexpression results in increased neuronal number following 
differentiation of mC-BDNF engineered NSCs. Micrographs showing Tuj1 immunostained 
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differentiated NSCs in (A) untransfected and (B) mC-BDNF-GFP engineered groups at 5 
days post-transfection. Insets show corresponding DAPI-stained cells, arrowheads in (B) 
point to distinct neuronal clusters. (C) Bar graph displaying the proportions of neurons, 
astrocytes and oligodendrocytes generated from differentiated untransfected and mC-BDNF-
GFP engineered NSCs. (D) Representative triple merged micrograph of a GFP
+
 astrocyte- 
the predominant daughter cell population observed to be transfected post-differentiation. (E) 
GFP
+
 cells (displaying an astrocytic morphology) were BDNF
+ 
(inset shows BDNF 
accumulation within the same cell) demonstrating that astrocytes derived from mC-
engineered NSCs express the therapeutic protein. Representative triple merged micrographs 
of (F) Tij1
+
 neurons and (G) an MBP
+
 oligodendrocyte derived from mC-engineered NSCs; 
both were rarely observed to be transfected (an example each shown by the arrow in (F) and 
G inset). *p < 0.05, versus untransfected NSCs (student’s t-test), n=3 cultures. 
 
3.6. BDNF overexpression enhances neurite outgrowth  
Augmented BDNF levels also resulted in enhanced neurite outgrowth. The need for 
accelerated neurite outgrowth is key as mature neurons are required in order to facilitate the 
establishment and integration of functional neuronal networks with the host tissue.[52] 
Morphological observations showed obvious differences in neurite length at the 2 week and 4 
week time points (Fig. 6 A-B, D-E). Neurite length assessments were carried out at the 2 
week time point as optimal measurements for neurite length were obtained for both 
conditions (i.e. no overlapping neurites). Neurite length was dramatically increased in mC-
BDNF-GFP treated cells compared to untransfected cells (Fig. 6C). Experimental evidence of 
BDNF-mediated neurite outgrowth has been shown in both NSC derived neurons as well as 
mature neuronal cultures [45,53]. Though BDNF levels continually decreased over the four 
week time period (Fig. 6F), it is important to note that this is an underrepresentation of in 
vivo BDNF levels as media was changed every few days, therefore diluting the actual BDNF 
levels in this in vitro assay. In the case of therapeutic gene delivery, a tapered profile of 
therapeutic expression is favoured following transplantation as (i) the functional outcome can 
be achieved early on  i.e. increased neuronal number and enhanced maturation (ii) molecular 
expression of neurotrophic factors profiles change over time  therefore reducing the need for 
specific therapeutic factors.  
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Fig. 6. Augmented BDNF levels in mC-engineered NSCs accelerate neuronal maturation. 
Representative micrographs of Tuj1-immunostained differentiated NSCs for (A) untransfected 
and (B) mC-BDNF-GFP engineered cells, 2 weeks post-transfection. (C) Bar graph showing 
quantitative analysis of average neurite length between both groups at 2 weeks post-
transfection. Representative micrographs of Tuj1-immunostained differentiated NSCs for (D) 
untransfected and (E) mC-BDNF-GFP engineered cells, 4 weeks post-transfection. (F) 
Temporal secretion profile of BDNF levels (measured by ELISA) in media supernatants over 
4 weeks post-transfection. The insets in A-B and D-E show corresponding DAPI-stained 
images. **p < 0.01 versus untransfected control (student’s t-test), n=3 cultures. 
 
 
 
3.7 Clinical implications of minicircle/magnetofection engineered NSCs expressing 
BDNF for regenerative neurology 
 
This is the first demonstration of mC technology used in conjunction with MNPs for delivery 
of a neurotherapeutic biomolecule. Using reporter gene sequences, we previously suggested 
that such an approach could be of high clinical relevance in terms of safety, transfection 
efficiency and sustained gene transfer (Part I). The target protein, BDNF, is a major 
therapeutic candidate for a number of neurological disorders and injuries such Alzheimer’s 
disease, stroke and spinal cord injury as demonstrated in rodent and primate preclinical 
models [6,54–56]. The CNS has a limited capacity to generate neurons following injury, as 
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the microenvironment within the site of pathology is unfavourable for the survival and 
differentiation of neurons. BDNF overexpression (through the paracrine effect conferred by 
the predominantly engineered astrocytic population) can address this issue in three ways. 1) 
generation of higher neuronal numbers 2) neuroprotection of differentiated neurons and 3) 
accelerated levels of neuronal maturation. We show the potential of mC-engineered NSCs to 
contribute to such regenerative events, findings that are in line with several in vitro, ex vivo 
and in vivo studies. We consider the combination of approaches used here to be safer, cost-
effective and less time-consuming for the clinic, in comparison to viral-mediated gene 
delivery approaches and systemic BDNF administration. Further, neurotrophin production 
has high manufacturing costs [57] and systemic neurotrophic factor  administration including 
BDNF has been shown to be less efficient as only a small amounts of the protein can cross 
the blood brain barrier and can result in undesirable side effects. [58] Given the pathology–
homing nature of NSCs towards a site of injury, our combinatorial approach could enable a 
more localised delivery of the therapeutic gene enabling in situ biomolecule expression. In 
the context of improved safety and efficacy of gene delivery, the entire mC construct used in 
this study is biocompatible including the promoter (human EF1a) as opposed to the widely 
used virus-derived promoters such as CMV. Additionally, using mCs without the reporter 
gene (further reducing size) could enable much higher and sustained levels.  
 
Accelerated and effective functional therapeutic outcomes require delivery of multiple genes 
simultaneously. For example, to further increase neuronal yield, a combination of BDNF, b-
FGF and IGF1 may be required [59]. The mC system can enable a versatile yet flexible 
therapeutic approach in which a number of different neurotrophic factors can be delivered 
simultaneously to NSCs in order to achieve optimal therapeutic outcome in vivo [23]. This is 
especially pertinent in the context of addressing the complexity of neural pathology where a 
combinatorial therapy can also allow multiple genes to be expressed simultaneously to 
address multiple regenerative targets, in other words a ‘molecular cocktail’. As an example, 
these could include BDNF for axonal outgrowth, chondroitinase ABC for breakdown of 
repair-inhibitory matrix glycoproteins and VEGF to promote cell survival and angiogenesis 
(potentially via use of multicistronic plasmids), without greatly increasing vector size. We 
have previously demonstrated that MNPs can mediate delivery of two different reporter genes 
(GFP and RFP) to NSC neurospheres and monolayers (with up to 90% of transfected cells 
co-expressing both markers) [23] indicating that delivery of multiple therapeutic genes using 
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mC technology is entirely feasible. This can offer flexibility for ‘tailor-made gene therapy’ 
depending on type and severity of the pathology being treated.  
 
Further advantages of our approach have been discussed previously (see manuscript Part I). 
Briefly, both mCs and MNPs can be economically produced at a large scale at high purity 
with the development of novel technologies such as affinity-based chromatographic 
purification and flame spray method [60,61]. Additionally, the robust one-step protocol used 
here requires minimal training and basic laboratory equipment/containment level. 
mC/magnetofection technology could be also be exploited for the delivery of recombinant 
proteins such as Tau-neutralising antibodies [62], the prevalent component in neurofibrillary 
tangles,  brain-penetrating biologic TNF-inhibitor in Parkinson’s disease [63] and other 
emergent biologics currently being developed for effective neuro-therapeutics.  
 
4. Conclusion 
Our findings provide the first proof that mC DNA vectors in conjunction with nanoparticle 
carriers, can mediate delivery of a gene encoding a major neurotrophic factor, BDNF, which 
enhances neurogenesis and exerts neuroprotective effects. The mC DNA vector system 
allows for the restrictions imposed by increased plasmid size (leading to decreased 
nanoparticle-mediated cellular transfection) to be reduced. Our procedures were associated 
with high safety, and clear neuroregenerative outcomes could be observed in terms of 
increased genesis of neurons/enhanced neuronal maturation, consistent with the reported role 
of BDNF.  Based on these findings, we consider that a fusion of mC DNA vector technology 
with nanoparticle vehicles significantly enhances the functionality of nanoparticle vector 
platforms, and could come to represent the genetic modification method of choice for clinical 
cell therapies. Additionally, given the progression of both neurotrophins and NSCs to clinical 
trials, we suggest that mC based engineering for translational applications appears realistic. 
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Graphical abstract 
 
 
 
Genetic engineering of neural stem cell transplant populations to overexpress brain 
derived neurotrophic factor using minicircle DNA vectors and nanoparticle vehicles 
appears feasible and safe. The procedure results in enhanced genesis of neurons 
and neuronal maturation.  
